The latest price target for CollPlant Biotechnologies (NASDAQ:CLGN) was reported by HC Wainwright & Co. on May 30, 2024. The analyst firm set a price target for $11.00 expecting CLGN to rise to within 12 months (a possible 126.20% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for CollPlant Biotechnologies (NASDAQ:CLGN) was provided by HC Wainwright & Co., and CollPlant Biotechnologies reiterated their buy rating.

There is no last upgrade for CollPlant Biotechnologies

There is no last downgrade for CollPlant Biotechnologies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CollPlant Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CollPlant Biotechnologies was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.

While ratings are subjective and will change, the latest CollPlant Biotechnologies (CLGN) rating was a reiterated with a price target of $11.00 to $11.00. The current price CollPlant Biotechnologies (CLGN) is trading at is $4.86, which is out of the analyst’s predicted range.